Andreas Hollenstein
Sr. Principal Scientist, Immunosafety Roche
Seminars
Tuesday 7th July 2026
The Engineering Advantage: De-Risking Bispecific Antibodies from Concept to Clinic
1:00 pm
With bispecifics and T-cell engagers advancing rapidly, early-stage development carries significant translational, immunogenicity, and safety risk. This workshop will explore how to design integrated preclinical packages that better predict human pharmacology, safety, and immune-related liabilities, enabling more confident progression into the clinic. Participants will learn how to align mechanism-of-action, safety, and immunogenicity assessments to build confidence in human outcomes and accelerate early clinical decision-making.
This workshop will gather experts to discuss:
- Optimise biologics for safety, efficacy and immunogenicity to confidently de-risk bispecifics and TCEs before entering clinical studies
- Identify and mitigate immune-related and safety liabilities early, strengthening predictivity and reducing clinical development risk
- Leverage mechanism-of-action insights to integrate safety and immunogenicity considerations into preclinical packages to accelerate regulatory approval and clinic readiness
Monday 8th June 2026
Fireside Chat: How Can We Predict Clinical Reality Through Preclinical Models & Translational Strategies?
12:30 pm
- Which preclinical models have proven most predictive for bispecifics, TCEs, and ADCs- including safety and immunogenicity risk, and which consistently fail to translate?
- How do teams combine in vitro, in vivo, and computational approaches to reduce uncertainty before first-in-human studies?
- What translational signals provide sufficient confidence to advance a program, and how do teams actively manage remaining risk?
